We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current CHRO market cap is 10.61M. The company's latest EPS is USD -1.2798 and P/E is -1.44.
Quarter End | ||
---|---|---|
USD (US$) | USD (US$) | |
Total Revenue | ||
Operating Income | ||
Net Income |
Year End 31 December 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 |
Operating Income | -2.32M | -6.86M |
Net Income | -2.46M | -7.38M |
Quarter End | ||
---|---|---|
USD (US$) | USD (US$) | |
Total Assets | ||
Total Liabilities | ||
Total Equity |
Year End 31 December 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Total Assets | 55k | 96k |
Total Liabilities | 3.76M | 6.54M |
Total Equity | -3.71M | -6.45M |
Market Cap | 10.61M |
Price to Earnings Ratio | -1.44 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 110.84 |
Price to Book Ratio | -1.65 |
Dividend Yield | - |
Shares Outstanding | 5.77M |
Average Volume (1 week) | 21.47k |
Average Volume (1 Month) | 17.95k |
52 Week Change | -69.33% |
52 Week High | 6.00 |
52 Week Low | 1.21 |
Spread (Intraday) | 0.18 (9%) |
Company Name | Chromocell Therapeutics Corporation |
Address |
108 west 13th st wilmington, delaware 19801 |
Website | https://chromocell.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions